Mid
U
URGNAI Stock Diagnostic Report
UroGen targets $260M-$270M 2026 opex as ZUSDURI grows 73% q/q
UroGen Pharma's ZUSDURI has grown by 73% compared to the previous quarter and has set an operational cost target for 2026.
View Source Article ↗
AI CATALYST SCORE78 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
URGN Analysis History (Last 30 Days)